Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
information fournie par Boursorama CP 09/11/2021 à 14:00

Data support BT-001’s unique dual mode of action

Strasbourg, France, and Lund, Sweden, November 9, 2021, 2:00 pm CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announce preclinical data supporting the mode of action of BT-001, their novel dual mechanism-of-action oncolytic Vaccinia virus. The data demonstrate high intratumoral expression of an immune checkpoint-inhibiting antibody and robust anti-tumoral activity in several tumor models.

.../...

Valeurs associées

TRANSGENE
0,7550 EUR Euronext Paris +3,85%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
71,84 +0,39%
Or
4 197,33 +0,52%
2CRSI
36,32 -3,76%
CAC 40
8 508,07 +0,39%
EUR/USD SPOT
1,14335 -0,04%
Chargement...

Pages les plus populaires

L'offre BoursoBank